Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response

After neoadjuvant chemoradiotherapy for esophageal adenocarcinoma, up to 29% of patients have a pathological complete response (pCR). What to do afterward is still under debate. The aim of this prospective study was to define which local markers of immune response might act as predictors of pCR and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotsafti, Andromachi, Scarpa, Melania, Cavallin, Francesco, Fassan, Matteo, Salmaso, Roberta, Porzionato, Andrea, Saadeh, Luca, Cagol, Matteo, Alfieri, Rita, Castoro, Carlo, Rugge, Massimo, Castagliuolo, Ignazio, Scarpa, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458640/
https://www.ncbi.nlm.nih.gov/pubmed/32923165
http://dx.doi.org/10.1080/2162402X.2020.1804169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458640/
https://www.ncbi.nlm.nih.gov/pubmed/32923165
http://dx.doi.org/10.1080/2162402X.2020.1804169

Ejemplares similares